Press Releases


showing 1-10 of 138

Funding for HIV Survives Extreme Cuts Proposed By House Republicans

Final FY24 Bill Includes Calls for HHS/CDC to Increase PrEP Access 21 March 2024 – PrEP4All, AVAC, HIVMA, and the PrEP in Black America coalition celebrate Congress’ decision to both fund domestic HIV programs at the same level as last year...

March 2024

New COMPASS Governance Structure to Accelerate HIV Policy and Advocacy

AVAC and Pangaea Zimbabwe are thrilled to announce Pangaea Zimbabwe's new leadership of COMPASS Africa, a historic milestone in the development of innovative models for power-sharing in coalition and an important step toward decolonizing global...

January 2024

The Search for an HIV Vaccine Must Continue

New York, 6 December 2023 – Today the PrEPVacc trial team announced at a special session at the International Conference on AIDS and STIs in Africa (ICASA) in Harare, Zimbabwe, that they were stopping vaccinations in the...

Prevention Option:

December 2023

AVAC Applauds the Selection of Dr. Jeanne Marrazzo as New Director of NIAID  

AVAC enthusiastically applauds the selection of Jeanne Marrazzo, MD, to serve as the new director of the NIH’s National Institute of Allergy and infectious Disease (NIAID). Dr. Marrazzo brings unparalleled leadership and research expertise to this pivotal role at NIAID, which oversees some of the largest investments to advance research on HIV and sexually transmitted infections in the world, at such a critical moment in global health science and politics. 

August 2023

AVAC Condemns Uganda’s Anti-Homosexuality Act 2023

AVAC strongly condemns Uganda’s new Anti-Homosexuality Act of 2023 that President Yoweri Museveni signed into law and stands in solidarity with the LGBTQIA+ community in Uganda.

May 2023

AVAC Condemns Court Decision that Tramples Human Rights, Endangers Evidence-Based Medical Care and Sets a Dangerous Precedent

AVAC strongly condemns the decision by a federal judge in Texas who issued an unprecedented preliminary injunction that suspends the US Food and Drug Administration’s (FDA) approval of mifepristone, a safe and effective abortion medication...

April 2023

PrEP Advocates Convene Virtual Town Hall Responding to Braidwood v. Becerra

Hundreds of HIV prevention advocates nationwide convened on Tuesday to discuss the implications of Judge Reed O’Connor’s ruling in the Texas Braidwood v. Becerra case that could impact access to PrEP and other preventive health interventions for...

April 2023

AVAC Condemns Court Decision that Endangers Access to PrEP and Other Critical, Life-Saving Prevention Services

This ruling will not only affect HIV prevention services, but endangers access to contraception, vaccinations, routine health screenings and a wide range of prevention services.

March 2023

AVAC Condemns Uganda’s Anti-Homosexuality Bill 2023

AVAC condemns the legislation and stands in solidarity with the LGBTQIA+ community in Uganda who face threats to their lives, draconian prison terms, and even the prospect of death sentences.

March 2023

HIV Vaccine Research Must Continue Following Disappointing Result from Mosaico Trial

Janssen Pharmaceutical Companies of Johnson & Johnson and partners announced that the Mosaico study, a large-scale HIV vaccine efficacy study also known as HVTN 706/HPX3002, was stopped early for non-efficacy.

Prevention Option:

February 2023

showing 1-10 of 138